AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win 4/30/2024

Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership 4/30/2024

Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique 4/30/2024

A Takeda Oncology Leader’s Passion Fuels A Patient-First Approach 4/30/2024

Ono to Buy Deciphera for $2.4B, Looks to Expand Cancer Pipeline and US Footprint 4/29/2024

BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases 4/29/2024

FDA Approves First Targeted Treatment for WHIM Syndrome 4/29/2024

J&J-Partnered Addex Fails Phase II Epilepsy Study, Mulls Future of Candidate 4/29/2024

Bavarian Nordic’s Mpox Vaccine Safe, Effective at Lower Doses: Study 4/29/2024

Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT 4/29/2024

Pharma R&D ROI Spikes in 2023 as ‘Breakthroughs’ Re-Energize Industry: Report 4/29/2024

What’s Next for Obesity Therapeutics? Higher Quality Weight Loss 4/29/2024

As Autism Cases Rise, Biopharma Springs Into Action 4/29/2024

5 Mid-Stage ALS Drugs to Watch 4/29/2024

Opinion: Larimar Could Compete with Biogen in Friedreich’s Ataxia 4/29/2024

AbbVie Raises 2024 Profit Outlook, Reports Strong Q1 Sales for Skyrizi and Rinvoq 4/26/2024

Pfizer Secures FDA Approval for Hemophilia B Gene Therapy, Launches Warranty 4/26/2024

Gilead Touts 5% Revenue Jump, Positions for 2024 Growth and Culls Pipeline 4/26/2024

GSK Sues Pfizer and BioNTech Over Alleged COVID-19 Patent Infringement 4/26/2024

Cigna’s Evernorth to Offer Humira Biosimilar with No Out-of-Pocket Cost 4/26/2024